[{"data":1,"prerenderedAt":48},["ShallowReactive",2],{"q-nurse-113-3-basic-medicine-040":3},{"subject":4,"subjectSlug":5,"subjectFullName":6,"question":7,"related":24},"基礎醫學","basic-medicine","基礎醫學(包括解剖學、生理學、病理學、藥理學、微生物學與免疫學)",{"id":8,"webId":9,"year":10,"session":11,"subject":4,"number":12,"stem":13,"options":14,"answer":19,"answerNote":20,"images":21,"explanation":22,"freq":23},"nurse-113-3-基礎醫學-040","nurse-113-3-basic-medicine-040",113,3,40,"下列那一個藥物屬於 topoisomerase I 抑制劑？",{"A":15,"B":16,"C":17,"D":18},"vinblastine","paclitaxel","irinotecan","azacitidine","C",null,[],"本題考點在於抗癌藥物依作用標的的機轉分類，須辨識 topoisomerase I（拓樸異構酶 I）抑制劑。拓樸異構酶 I 負責切開單股 DNA 以釋放複製時的超螺旋張力，其抑制劑會穩定「酵素—DNA」切割複合體、造成 DNA 斷裂。irinotecan 為喜樹鹼衍生物，正是典型 topoisomerase I 抑制劑，選 C。vinblastine 為長春花生物鹼，結合 tubulin 抑制微管聚合、阻止紡錘體形成；paclitaxel 為紫杉醇，機轉相反、穩定微管使其無法解聚，兩者皆作用於微管而非拓樸酶；azacitidine 為胞嘧啶核苷類似物、屬去甲基化抗代謝藥，作用於 DNA 甲基化。三者均非拓樸異構酶 I 抑制劑。",1,[25,29,33,36,40,44],{"webId":26,"stem":27,"number":23,"year":28,"session":23},"nurse-106-1-basic-medicine-001","下列有關表皮的敘述，何者正確？",106,{"webId":30,"stem":31,"number":32,"year":28,"session":23},"nurse-106-1-basic-medicine-002","下列何者在組織學特徵上可區分為絲球帶（zona glomerulosa）、束狀帶（zona fasciculata）、網狀帶（zona reticularis）？",2,{"webId":34,"stem":35,"number":11,"year":28,"session":23},"nurse-106-1-basic-medicine-003","顴弓（zygomatic arch）是由顴骨與下列何者共同組成？",{"webId":37,"stem":38,"number":39,"year":28,"session":23},"nurse-106-1-basic-medicine-004","下列何者參與形成踝關節？",4,{"webId":41,"stem":42,"number":43,"year":28,"session":23},"nurse-106-1-basic-medicine-005","下列何者是維持背部直立最重要的肌肉？",5,{"webId":45,"stem":46,"number":47,"year":28,"session":23},"nurse-106-1-basic-medicine-006","行走於前臂的內側，並與上臂深層的靜脈會合成腋靜脈的是那一條血管？",6,1783840771672]